Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
| Autor: | Yi-Hsn Yang, Yueh-Lung Peng, Chien-Ning Hsu, Chien-Te Lee, Yaw-Bin Huang, You-Lin Tain, Yen-Hsia Wen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_treatment 030232 urology & nephrology lcsh:Medicine urologic and male genital diseases Kidney Cohort Studies chemistry.chemical_compound 0302 clinical medicine Hyperuricemia lcsh:Science Aged 80 and over Multidisciplinary Middle Aged Prognosis Outcomes research Nephrology Female Febuxostat medicine.drug Glomerular Filtration Rate medicine.medical_specialty Allopurinol Urology Taiwan Renal function Therapeutics Article Gout Suppressants 03 medical and health sciences Medical research medicine Humans Renal replacement therapy Renal Insufficiency Chronic Aged 030203 arthritis & rheumatology business.industry lcsh:R medicine.disease Uric Acid Clinical trial chemistry Uric acid lcsh:Q business Kidney disease Follow-Up Studies |
| Zdroj: | Scientific Reports Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020) |
| ISSN: | 2045-2322 |
| Popis: | Whether the clinical trial treatment effect of urate-lowering therapy (ULT) in patient with chronic kidney disease (CKD) is generalizable to real-word settings is unclear. This study aimed to compare febuxostat with allopurinol for uric acid reduction and renal protection in patients with CKD. Adult CKD patients newly treated with ULT were identified using electronic health records from 2010 to 2015 from a large healthcare delivery system in Taiwan. Patients with renal replacement therapy or undergoing ULT for 80% of follow-up time with a reduction in mean SUA change. There were no significant differences in the mean eGFR changes over time between the febuxostat and allopurinol groups or in the risk of eGFR decline ≥30% of baseline. Febuxostat was associated with greater reduction in SUA level than allopurinol in patients with CKD. However, febuxostat and allopurinol showed no difference in renal function changes during study follow-up. These findings require further investigation with long-term follow up in CKD patients with hyperuricemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |